|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.20/--
|
企業價值
61.62M
|
資產負債 |
每股賬面淨值
3.50
|
現金流量 |
現金流量率
--
|
損益表 |
收益
279.00K
|
每股收益
0.17
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/11/10 13:06 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. |